{
    "clinical_study": {
        "@rank": "100860", 
        "arm_group": [
            {
                "arm_group_label": "Theramine", 
                "arm_group_type": "Active Comparator", 
                "description": "2 capsules before breakfast and dinner (BID) for 16 weeks."
            }, 
            {
                "arm_group_label": "placebo (l-alanine)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "2 capsules before breakfast and dinner (BID) for 16 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy of Theramine\u00ae as a preventative for\n      migraine headaches."
        }, 
        "brief_title": "Theramine\u00ae in the Prevention of Migraine Headache", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Migraine Headaches", 
        "condition_browse": {
            "mesh_term": [
                "Headache", 
                "Migraine Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION CRITERIA: The inclusion criteria will be the following:\n\n          1. (male and female) 18-65 years of age\n\n          2. Women of child-bearing potential, has a negative pregnancy test (urine or serum) at\n             screen, and agrees to one of the following:\n\n               1. Complete abstinence from intercourse from 2 weeks prior to administration of the\n                  investigational product, throughout the study, and for a time interval (5 days)\n                  after completion or premature discontinuation from the study,\n\n               2. History of bilateral tubal ligation,\n\n               3. Hormonal Contraception (oral, patch, etc.) as approved by the Investigator,\n\n               4. Sterilization of male partner; or,\n\n               5. Any intrauterine device (IUD),\n\n               6. Spermicide plus a mechanical barrier (e.g., spermicide plus a male condom or\n                  spermicide plus a female diaphragm); or,\n\n               7. Any other barrier methods (only if used in combination with any of the above\n                  acceptable methods);\n\n          3. Diagnosis of migraine headache (ICHD 1.1-1.5) as determined by criteria established\n             by the International Classification of Headache Disorder (ICHD-II).\n\n          4. 4-14 days per month with migraine averaged over past 3 months, as self reported by\n             subject.\n\n          5. Migraines symptoms must have been present for at least one year prior to enrollment\n             in the study.\n\n          6. The onset of migraine symptoms must have occurred before age 50.\n\n          7. Is medically stable as determined by the Investigator.\n\n          8. If taking any concomitant preventative medication(s), is on a stabilized dosage at\n             the discretion of the investigator.\n\n          9. Is willing to stay on current preventative medication(s) for the duration of the\n             study.\n\n         10. Is able to take oral medication, adhere to the medication regimens and perform study\n             procedures.\n\n         11. Is able to understand and communicate intelligibly with the study observer.\n\n         12. Is able to read and comprehend written instructions and be willing to complete all\n             procedures and assessments required by this protocol.\n\n         13. Is able to demonstrate the willingness to participate by signing and understanding an\n             informed consent after full explanation of the study.\n\n        EXCLUSION CRITERIA: The exclusion criteria will be the following:\n\n          1. Is pregnant, actively trying to become pregnant, or breast feeding.\n\n          2. A diagnosis of medication overuse headaches as determined by the investigator.\n\n          3. Chronic medical illnesses (eg. lupus, malignancy, infections, sarcoidosis) that could\n             potentially modulate the frequency of migraine headache.\n\n          4. Has evidence of alcohol or substance abuse within the last year or any concurrent\n             medical or psychiatric condition which, in the investigator's judgment, will likely\n             interfere with the study conduct, subject cooperation, or evaluation and\n             interpretation of the study results, or which otherwise contraindicates participation\n             in this clinical trial.\n\n          5. Chronic daily headache (\u2265 15 days per month with headache of any kind) averaged over\n             past 3 months.\n\n          6. Abnormal creatinine, BUN, and/or Liver Function Enzymes will be assessed and\n             exclusion will be at the discretion of the Investigator.\n\n          7. Allergy or hypersensitivity to any ingredients in Theramine\u00ae including\n             arginine-containing preparations and whey protein (milk)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01944059", 
            "org_study_id": "VM-2013-001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Theramine", 
                    "placebo (l-alanine)"
                ], 
                "description": "Theramine\u00ae is a prescription medical food that is composed of variety of amino acids and/or their precursors.", 
                "intervention_name": "Theramine (medical food/old drug)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Theramine", 
                    "placebo (l-alanine)"
                ], 
                "description": "Theramine like placebo comparator", 
                "intervention_name": "Placebo (l-alanine)", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 6, 2014", 
        "location": {
            "contact": {
                "email": "ucmigraine@gmail.com", 
                "last_name": "Karen Mandell", 
                "phone": "513-614-7475"
            }, 
            "facility": {
                "address": {
                    "city": "Cincinnati", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "45219"
                }, 
                "name": "University Cincinnati Physicians Company"
            }, 
            "investigator": {
                "last_name": "Vincent Martin, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Role of Theramine\u00ae in the Prevention of Migraine Headache: A Pilot Study", 
        "overall_contact": {
            "email": "ucmigraine@gmail.com", 
            "last_name": "Karen Mandell", 
            "phone": "513-614-7475"
        }, 
        "overall_contact_backup": {
            "email": "MBreitstein@ptlcentral.com", 
            "last_name": "Mira Breitstein", 
            "phone": "310-474-9809", 
            "phone_ext": "109"
        }, 
        "overall_official": {
            "affiliation": "University of Cincinnati", 
            "last_name": "Vincent Martin, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome measure will be the frequency of migraine and all headache days in the Theramine active group versus the Theramine placebo group during the treatment period.", 
            "measure": "Number of migraine/headache days", 
            "safety_issue": "No", 
            "time_frame": "5 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01944059"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Targeted Medical Pharma", 
            "investigator_full_name": "Vincent Martin, MD", 
            "investigator_title": "Vincent Martin MD, University of Cincinnati Physicians Company", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The percent change in migraine and headache frequency will be defined as [frequency/baseline phase - frequency/treatment phase] divided by [frequency/baseline phase].", 
                "measure": "Percent Change in Migraine and Headache Frequency", 
                "safety_issue": "No", 
                "time_frame": "4-6 months"
            }, 
            {
                "description": "Differences in the scores for the HIT-6 disability inventory between baseline and the last study visit will be analyzed.", 
                "measure": "HIT-6", 
                "safety_issue": "No", 
                "time_frame": "4-6 months"
            }
        ], 
        "source": "Targeted Medical Pharma", 
        "sponsors": {
            "collaborator": {
                "agency": "Targeted Medical Pharma", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Vincent Martin, MD", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}